newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//Breitbart News Network
Eli Lilly is acquiring three vaccine companies in deals totaling nearly $4 billion.
Eli Lilly is acquiring Curevo, LimmaTech Biologics, and Vaccine Company for nearly $4 billion total.
KEY POINTS
Curevo’s lead vaccine amezosvatein targets adult shingles and uses a novel synthetic adjuvant.
LimmaTech Biologics focuses on vaccines for sexually transmitted infections and Staphylococcus aureus.
Vaccine Company is advancing Vivo Nanoparticle technology for delivering treatments against viral pathogens like Epstein-Barr Virus.
Eli Lilly seeks to shift focus from treating diseases to preventing them at their source through vaccines.
May 26 (UPI) — Eli Lilly announced Tuesday that it is acquiring three vaccine companies in deals totaling nearly $4 billion.
Eli LIlly is acquiring Curevo Inc., LimmaTech Biologics AG and Vaccine Company, Inc., expanding its research and development in vaccines for infectious diseases. The deal for Vaccine Company is the largest at $1.55 billion, followed by Curevo at $1.5 billion and LimmaTech Biologics AG for up to $780 million in cash.
“These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences,” Daniel M. Skovronsky, chief scientific and product officer and president of Lilly Research Laboratories, said in a statement.
“Decades of evidence now link common infections to diseases that potentially emerge years later, including neurological disease, cancer and infertility. And as antimicrobial resistance erodes our ability to treat bacterial infections, vaccines are increasingly the only path to prevention. Combining these companies’ platforms and teams with Lilly’s global scale positions us to change that trajectory.”
Following the news of the acquisitions, shares in Eli Lilly went up 0.9% at the open of Tuesday’s market.
Curevo’s key vaccine amezosvatein is for adult shingles. It was developed with a synthetic adjuvant that enhances the body’s immune response. It has been engineered to improve tolerability, which is a barrier to vaccination rates.
LimmaTech Biologics’ vaccines are developed for use against bacterial pathogens, particularly sexually transmitted infections like Neisseria gonorrhoeae and Chlamydia trachomatis, as well as Staphylococcus aureus, a common skin infection.
The Vaccine Company is developing its proprietary Vivo Nanoparticle technologies for effective drug delivery to combat viral pathogens like the Epstein-Barr Virus.